Conceptus(R) to Present at the 24th Annual ROTH Conference
March 05 2012 - 5:30PM
Conceptus, Inc. (Nasdaq:CPTS), developer of the
Essure® procedure, the leading non-surgical permanent birth control
method, announced today that management is planning to present at
the 24th Annual ROTH Conference on Monday, March 12, 2012 at 1:30
p.m. Pacific time at the Ritz-Carlton in Laguna Niguel, California.
A live webcast of the presentation will be available on the
company's website at www.conceptus.com. When accessing the webcast
through the Conceptus site, select "Investors" then select "Events
and Presentations." The archived replay will be available
following the live presentation.
About the Essure® Procedure
The Essure procedure, FDA approved since 2002, is the first
permanent birth control method that can be performed in the comfort
of a physician's office in less than 10 minutes (average
hysteroscopic time) without hormones, cutting, burning or the risks
associated with general anesthesia or tubal ligation. Soft,
flexible inserts are placed in a woman's fallopian tubes through
the cervix without incisions. Over the next three months, the body
forms a natural barrier around and through the inserts to prevent
sperm from reaching the egg. Three months after the Essure
procedure, a doctor is able to perform an Essure Confirmation Test
to confirm that the inserts are properly placed and that the
fallopian tubes are fully blocked, allowing the patient to rely
upon Essure for permanent birth control.
The Essure procedure is 99.95% effective based on one year of
follow up with zero pregnancies reported in clinical trials, making
it the most effective form of permanent birth control on the
market. The procedure is covered by most public and private
insurance plans, and when it is performed in a doctor's office the
cost to the patient may be as low as a simple co-pay. Essure has
been proven and trusted by physicians since 2002, with more than
600,000 women worldwide having undergone the Essure procedure.
About Conceptus®, Inc.
Conceptus, Inc. is a leader in the design, development and
marketing of innovative solutions in women's healthcare. The
Company manufactures and markets the Essure procedure. The
Essure procedure is available in the United States, Europe,
Australia, New Zealand, Canada, Mexico, Central and South America
and the Middle East.
Please visit www.essure.com for more information on the Essure
procedure. Patients may call the Essure Information Center at
1-877-ESSURE-1 with questions or to find a physician in their
area.
The Conceptus, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7961
CC-3041 5MAR12F
CONTACT: Investor and Public Relations Contact:
Cindy Klimstra
(650) 962-4032
cindy_klimstra@conceptus.com
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Conceptus, Inc. (MM) (NASDAQ:CPTS)
Historical Stock Chart
From Jul 2023 to Jul 2024